244 related articles for article (PubMed ID: 8199696)
1. Effects of pravastatin and ursodeoxycholic acid on cholesterol and bile acid metabolism in patients with cholesterol gallstones.
Okamoto S; Nakano K; Kosahara K; Kishinaka M; Oda H; Ichimiya H; Chijiiwa K; Kuroki S
J Gastroenterol; 1994 Feb; 29(1):47-55. PubMed ID: 8199696
[TBL] [Abstract][Full Text] [Related]
2. Hepatic cholesterol and bile acid metabolism in subjects with gallstones: comparative effects of short erm feeding of chenodeoxycholic and ursodeoxycholic acid.
Carulli N; Ponz De Leon M; Zironi F; Pinetti A; Smerieri A; Iori R; Loria P
J Lipid Res; 1980 Jan; 21(1):35-43. PubMed ID: 7354253
[TBL] [Abstract][Full Text] [Related]
3. The effect of ursodeoxycholic acid on the relative expression of the lipid metabolism genes in mouse cholesterol gallstone models.
Fan N; Meng K; Zhang Y; Hu Y; Li D; Gao Q; Wang J; Li Y; Wu S; Cui Y
Lipids Health Dis; 2020 Jul; 19(1):158. PubMed ID: 32615989
[TBL] [Abstract][Full Text] [Related]
4. Effect of ursodeoxycholic acid on hepatic cholesterol metabolism.
Einarsson K
Scand J Gastroenterol Suppl; 1994; 204():19-23. PubMed ID: 7824873
[TBL] [Abstract][Full Text] [Related]
5. Effects of combined treatment with pravastatin and ursodeoxycholic acid on hepatic cholesterol metabolism.
Hillebrant CG; Nyberg B; Gustafsson U; Sahlin S; Björkhem I; Rudling M; Einarsson C
Eur J Clin Invest; 2002 Jul; 32(7):528-34. PubMed ID: 12153554
[TBL] [Abstract][Full Text] [Related]
6. Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients.
Hillebrant CG; Axelson M; Björkhem I; Wang FH; Nyberg B; Einarsson C
Eur J Clin Invest; 1998 Apr; 28(4):324-8. PubMed ID: 9615912
[TBL] [Abstract][Full Text] [Related]
7. The effects of ursodeoxycholic acid on serum and biliary noncholesterol sterols in patients with gallstones.
Miettinen TE; Tarpila S; Gylling H
Hepatology; 1997 Mar; 25(3):514-8. PubMed ID: 9049189
[TBL] [Abstract][Full Text] [Related]
8. Ursodeoxycholic acid treatment in cholesterol gallstone disease: effects on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, biliary lipid composition, and plasma lipid levels.
Angelin B; Ewerth S; Einarsson K
J Lipid Res; 1983 Apr; 24(4):461-8. PubMed ID: 6854153
[TBL] [Abstract][Full Text] [Related]
9. Effect of pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on hepatic cholesterol 7 alpha-hydroxylase, acyl-coenzyme A: cholesterol acyltransferase, and bile lipid secretion in the hamster with intact enterohepatic circulation.
Hayashi K; Noshiro M; Kurushima H; Kuga Y; Nomura S; Ohkura Y; Ohtani H; Kurokawa J; Tanaka K; Yasunobu Y
Atherosclerosis; 1994 Dec; 111(2):183-9. PubMed ID: 7718020
[TBL] [Abstract][Full Text] [Related]
10. Effect of withdrawal of pravastatin on biliary lipid composition in humans.
Muraca M; Baggio G; Vilei MT; Martini S; Cianci V; Crepaldi G
Atherosclerosis; 1996 Jun; 123(1-2):133-7. PubMed ID: 8782844
[TBL] [Abstract][Full Text] [Related]
11. A combination of chenodeoxycholic acid and ursodeoxycholic acid is more effective than either alone in reducing biliary cholesterol saturation.
Podda M; Zuin M; Dioguardi ML; Festorazzi S; Dioguardi N
Hepatology; 1982; 2(3):334-9. PubMed ID: 7076116
[TBL] [Abstract][Full Text] [Related]
12. Effect of ursodeoxycholic acid administration on biliary lipid composition and bile acid kinetics in cholesterol gallstone patients.
Roda E; Roda A; Sama C; Festi D; Mazzella G; Aldini R; Barbara L
Dig Dis Sci; 1979 Feb; 24(2):123-8. PubMed ID: 428300
[TBL] [Abstract][Full Text] [Related]
13. Low-dose ursodeoxycholic acid prolongs cholesterol nucleation time in gallbladder bile of patients with cholesterol gallstones.
Jüngst D; Brenner G; Pratschke E; Paumgartner G
J Hepatol; 1989 Jan; 8(1):1-6. PubMed ID: 2921499
[TBL] [Abstract][Full Text] [Related]
14. Hepatic cholesterol metabolism in patients with gallstones.
Salen G; Nicolau G; Shefer S; Mosbach EH
Gastroenterology; 1975 Sep; 69(3):676-84. PubMed ID: 1158085
[TBL] [Abstract][Full Text] [Related]
15. The effects of the 3-hydroxy, 3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease.
Smit JW; van Erpecum KJ; Renooij W; Stolk MF; Edgar P; Doornewaard H; Vanberge-Henegouwen GP
Hepatology; 1995 Jun; 21(6):1523-9. PubMed ID: 7768495
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of chenodeoxycholic and ursodeoxycholic acids in obese patients. Effects on biliary lipid metabolism during weight maintenance and weight reduction.
Mazzella G; Bazzoli F; Festi D; Ronchi M; Aldini R; Roda A; Grigolo B; Simoni P; Villanova N; Roda E
Gastroenterology; 1991 Aug; 101(2):490-6. PubMed ID: 2065925
[TBL] [Abstract][Full Text] [Related]
17. Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans.
Lanzarotto F; Panarotto B; Sorbara R; Panteghini M; Pagani F; Sosta S; Lanzini A
Gut; 1999 Apr; 44(4):552-6. PubMed ID: 10075964
[TBL] [Abstract][Full Text] [Related]
18. Role of hydrophilic bile acids and of sterols on cholelithiasis in the hamster.
Singhal AK; Cohen BI; Finver-Sadowsky J; McSherry CK; Mosbach EH
J Lipid Res; 1984 Jun; 25(6):564-70. PubMed ID: 6547738
[TBL] [Abstract][Full Text] [Related]
19. Hepatic cholesterol and bile acid synthesis in Japanese patients with cholesterol gallstones.
Honda A; Yoshida T; Tanaka N; Matsuzaki Y; He B; Osuga T; Kobayashi N; Ozawa K
Gastroenterol Jpn; 1993 Jun; 28(3):406-14. PubMed ID: 8344502
[TBL] [Abstract][Full Text] [Related]
20. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
